Почетна › Плоскоклеточни карцином главе и врата › Arizona
Kliničke studije za Плоскоклеточни карцином главе и врата u državi Arizona
19 studija za Плоскоклеточни карцином главе и врата traži učesnike na lokacijama u državi Arizona.
Gradovi u državi Arizona
Zvanični tekst studije (na engleskom)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Mayo Clinic Hospital in Arizona, Phoenix
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05136196High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Arizona Center for Cancer Care - Gilbert, Gilbert
- Arizona Center for Cancer Care-Peoria, Peoria
- Arizona Center for Cancer Care - Biltmore, Phoenix
- и још 6
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06992427A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Ironwood Cancer and Research Center, Chandler
- University of Arizona Cancer Center, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07276399FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Mayo Clinic Hospital (Site #0147), Phoenix
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06788990A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Mayo Foundation for Medical Education and Research - Mayo Cl, Scottsdale
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06747585A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 111, Tucson
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT05914116A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- The University of Arizona Cancer Center, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07768189Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #67, Phoenix
- Exelixis Clinical Site #1, Tucson
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT05176483A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Gilbert
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT05877599Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Cancer Center at Saint Joseph's, Phoenix
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT02734537ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Ironwood Cancer & Research Centers, Chandler
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT05059444Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Banner MD Anderson Cancer Center, Gilbert
- Mayo Clinic Hospital in Arizona, Phoenix
- Banner University Medical Center - Tucson, Tucson
- и још 1
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Arizona Center for Cancer Care - Gilbert, Gilbert
- Arizona Center for Cancer Care-Peoria, Peoria
- Arizona Center for Cancer Care - Phoenix, Phoenix
- и још 3
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT06532279Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 6. 2026. · NCT04777994A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Banner MD Anderson Cancer Center, Gilbert
- The University of Arizona Cancer Center, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 4. 2026. · NCT06064877A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- HonorHealth Research Institute, Scottsdale
- The University of Arizona Cancer Center, Tucson
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT06778863A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Banner MD Anderson Cancer Center, Gilbert
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2025. · NCT06682793Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- HonorHealth Research Institute, Scottsdale
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 11. 2024. · NCT04787042A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
- Mayo Clinic Arizona, Phoenix
- HonorHealth Research and Innovation Institute, Scottsdale
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2024. · NCT06259552Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.